<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687072</url>
  </required_header>
  <id_info>
    <org_study_id>ARGX-113-2004</org_study_id>
    <nct_id>NCT04687072</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia</brief_title>
  <acronym>ADVANCE SC</acronym>
  <official_title>A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>argenx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>argenx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 3, multicenter, randomized, double-blinded, placebo-controlled,&#xD;
      parallel-group trial to evaluate the efficacy, safety, and effect on QoL/PRO of efgartigimod&#xD;
      PH20 SC treatment in adult patients with primary ITP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with chronic ITP with a sustained platelet count response defined as achieving platelet counts of ≥50×10E9/L for at least 4 of the 6 visits between week 19 and week 24 of the trial</measure>
    <time_frame>Up to 5 weeks (between week 19 -24)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extent of disease control defined as the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥50×10E9/L in the chronic ITP population</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the overall population (chronic and persistent ITP) with a sustained platelet count response defined as achieving platelet counts of ≥50×10E9/L for at least 4 of the 6 visits between week 19 and week 24</measure>
    <time_frame>Up to 5 weeks (between week 19-24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the overall population achieving platelet counts of ≥50×10E9/L for at least 6 of the 8 visits between week 17 and 24 of the trial</measure>
    <time_frame>Up to 7 weeks (between week 17-24)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the overall population with overall platelet response defined as achieving a platelet count of ≥50×10E9/L on at least 4 occasions at any time during the 24-week treatment period</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extent of disease control defined as the number of cumulative weeks until week 12 with platelet counts of ≥50×10E9/L in the overall population</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in the overall population with overall platelet response defined as achieving a platelet count of ≥50×10E9/L on at least 4 occasions at any time until week 12</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in platelet count at each visit in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response defined as the time to achieve 2 consecutive platelet counts of ≥50×10E9/L in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline in the overall population</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In patients with baseline platelet count of &lt;15×10E9/L, the number of cumulative weeks over the planned 24-week treatment period with platelet counts of ≥30×10E9/L and ≥20×10E9/L above baseline in the overall population</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of the World Health Organization (WHO)-classified bleeding events in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of the World Health Organization (WHO)-classified bleeding events in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of AEs, AEs of special interest (AESIs), and SAEs in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital sign measurement: blood pressure in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG: PR, QT and QRS interval in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory assessments: blood and urine analysis in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of receipt of rescue therapy (rescue per patient per month) in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients for whom dose and/or frequency of concurrent ITP therapies have increased at week 12 or later in the overall population</measure>
    <time_frame>Up to 23 weeks (between week 12-35)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PRO (Functional Assessment of Chronic Illness Therapy Fatigue Scale [FACIT-Fatigue] at planned visits in the overall population</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PRO Functional Assessment of Cancer Therapy questionnaire-Th6 [Fact-Th6]) at planned visits in the overall population</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PRO QoL (Short Form-36 [SF-36]) at planned visits in the overall population</measure>
    <time_frame>Up to 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antibodies to efgartigimod and/or rHuPH20 in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of antibodies to efgartigimod and/or rHuPH20 in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of antibodies to efgartigimod and/or rHuPH20 in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of neutralizing antibodies (NAb) against efgartigimod and/or rHuPH20, and titers of NAb against efgartigimod and/or rHuPH20 in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum efgartigimod concentration observed predose (Ctrough) in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics markers: total IgG and antiplatelet antibody levels in the overall population</measure>
    <time_frame>Up to 35 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Primary Immune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Efgartigimod PH20 SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving efgartigimod PH20 SC treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo PH20 SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receiving placebo PH20 SC treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Efgartigimod PH20 SC</intervention_name>
    <description>Subcutaneous injection with efgartigimod PH20 SC</description>
    <arm_group_label>Efgartigimod PH20 SC</arm_group_label>
    <other_name>ARGX-113 PH20 SC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo PH20 SC</intervention_name>
    <description>Subcutaneous injection with placebo PH20 SC</description>
    <arm_group_label>Placebo PH20 SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Ability to understand the requirements of the trial and provide written informed&#xD;
             consent (including consent for the use and disclosure of research-related health&#xD;
             information), willing and able to comply with the trial protocol procedures (including&#xD;
             attending the required trial visits)&#xD;
&#xD;
          -  Male or female, aged ≥18 years at the time the informed consent form (ICF) is signed.&#xD;
             Exceptions are made for The Republic of South Korea and Taiwan where, according to&#xD;
             local regulatory requirements, legal age is reached at 19 years and 20 years,&#xD;
             respectively.&#xD;
&#xD;
          -  Confirmed diagnosis of primary ITP made at least 3 months before randomization and&#xD;
             based on the American Society of Hematology Criteria, and no known etiology for&#xD;
             thrombocytopenia&#xD;
&#xD;
          -  Diagnosis supported by a response to a prior ITP therapy (other than TPO-RAs), in the&#xD;
             opinion of the investigator&#xD;
&#xD;
          -  Mean platelet count of &lt;30×10E9/L from at least 3 documented, qualifying counts within&#xD;
             the 3 preceding months where at least 2 of the qualifying counts must be taken during&#xD;
             the screening period: 1 platelet count collected during the screening period and the&#xD;
             predose platelet count on the day of randomization (visit 1). If the third count is&#xD;
             not available from the 3 preceding months, this third platelet count can be obtained&#xD;
             during the screening period.&#xD;
&#xD;
          -  A documented history of a platelet count of &lt;30×10E9/L before screening&#xD;
&#xD;
          -  At the start of the trial, the participant either takes concurrent ITP treatment(s)&#xD;
             and has received at least 1 prior therapy for ITP in the past, or the participant does&#xD;
             not take treatment for ITP (see note) but has received at least 2 prior treatments for&#xD;
             ITP. Participants receiving permitted concurrent ITP treatment(s) at baseline must&#xD;
             have been stable in dose and frequency for at least 4 weeks before randomization.&#xD;
&#xD;
        Permitted concurrent ITP medications include corticosteroids, danazol, vinca alkaloids,&#xD;
        oral immunosuppressants, dapsone, fostamatinib, and/or oral TPO-RAs.&#xD;
&#xD;
        Note: Participants not receiving concurrent ITP therapy are also eligible for the trial if&#xD;
        they have not received prior ITP therapy for at least 4 weeks before baseline, and 6 months&#xD;
        in case of prior ITP therapy with an anti-CD20 therapy (eg, rituximab).&#xD;
&#xD;
          -  Women of childbearing potential:&#xD;
&#xD;
               -  As defined in Woman of Childbearing Potential in the protocol, women of&#xD;
                  childbearing potential must have a negative serum pregnancy test at screening and&#xD;
                  a negative urine pregnancy test at baseline before trial medication can be&#xD;
                  administered&#xD;
&#xD;
               -  Must be on a stable regimen for at least 1 month of a highly effective or&#xD;
                  acceptable method of contraception during the trial and for 90 days after the&#xD;
                  last administration of IMP&#xD;
&#xD;
          -  Non-sterilized male participants who are sexually active with a female partner of&#xD;
             childbearing potential must use an acceptable method of contraception, ie, a condom&#xD;
             from signing the ICF through the last administration of the IMP. Male participants are&#xD;
             also not allowed to donate sperm during this time.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Secondary ITP/thrombocytopenia associated with another condition, eg, lymphoma,&#xD;
             chronic lymphocytic leukemia, viral infection, hepatitis, induced or alloimmune&#xD;
             thrombocytopenia, thrombocytopenia associated with myeloid dysplasia, or hematopoietic&#xD;
             stem cell transplant&#xD;
&#xD;
          -  Use of anticoagulants (eg, vitamin K antagonists, direct oral anticoagulants) within 4&#xD;
             weeks prior to randomization&#xD;
&#xD;
          -  Use of any transfusions within 4 weeks prior to randomization&#xD;
&#xD;
          -  Use of Ig (IV, SC, or intramuscular route) or plasmapheresis (PLEX) within 4 weeks&#xD;
             prior to randomization&#xD;
&#xD;
          -  Use of romiplostim within 4 weeks prior to randomization&#xD;
&#xD;
          -  Undergone splenectomy less than 4 weeks prior to randomization&#xD;
&#xD;
          -  Use of an investigational product within 3 months or 5 half-lives (whichever is&#xD;
             longer) before the first dose of the IMP&#xD;
&#xD;
          -  Use of any monoclonal antibody or Fc fusion proteins, other than those previously&#xD;
             indicated, within 6 months before the first dose of the IMP (eg, anti-CD20)&#xD;
&#xD;
          -  At the screening visit, clinically significant laboratory abnormalities as follows:&#xD;
&#xD;
             o Hemoglobin ≤9 g/dL&#xD;
&#xD;
          -  OR -&#xD;
&#xD;
             o International normalized ratio &gt;1.5 or activated partial thromboplastin time&#xD;
             &gt;1.5×upper limit of normal&#xD;
&#xD;
          -  OR -&#xD;
&#xD;
             o total IgG level &lt;6 g/L&#xD;
&#xD;
          -  History of malignancy unless deemed cured by adequate treatment with no evidence of&#xD;
             recurrence for ≥3 years before the first administration of IMP. Participants with the&#xD;
             following cancer can be included at any time:&#xD;
&#xD;
               1. Adequately treated basal cell or squamous cell skin cancer&#xD;
&#xD;
               2. Carcinoma in situ of the cervix&#xD;
&#xD;
               3. Carcinoma in situ of the breast or&#xD;
&#xD;
               4. Incidental histological finding of prostate cancer (TNM stage T1a or T1b)&#xD;
&#xD;
          -  Uncontrolled hypertension, defined as a repeated elevated blood pressure exceeding 160&#xD;
             mmHg (systolic) and/or 100 mmHg (diastolic) despite appropriate treatments&#xD;
&#xD;
          -  History of any major thrombotic or embolic event (eg, myocardial infarction, stroke,&#xD;
             deep venous thrombosis, or pulmonary embolism) within 12 months prior to randomization&#xD;
&#xD;
          -  History of coagulopathy or hereditary thrombocytopenia or a family history of&#xD;
             thrombocytopenia&#xD;
&#xD;
          -  Evidence of an active clinically significant bleeding of an organ or internal mucosal&#xD;
             bleeding, other than expected in ITP, that warrants emergent treatment or therapeutic&#xD;
             procedure based on the investigator's judgment (eg, intracranial hemorrhage, pulmonary&#xD;
             hemorrhage, bleeding with ongoing need for packed red blood cell transfusion)&#xD;
&#xD;
          -  Estimated high risk of a clinically significant bleeding of an organ or internal&#xD;
             mucosal bleeding, other than expected in ITP, that warrants emergent treatment or&#xD;
             therapeutic procedure according to the investigator's judgment&#xD;
&#xD;
          -  Clinical evidence of other significant serious diseases, have had a recent major&#xD;
             surgery, or who have any other condition in the opinion of the investigator, that&#xD;
             could confound the results of the trial or put the participant at undue risk&#xD;
&#xD;
          -  Positive serum test at screening for an active viral infection with any of the&#xD;
             following conditions:&#xD;
&#xD;
               1. Hepatitis B virus (HBV) that is indicative of an acute or chronic infection,&#xD;
                  unless associated with a negative HBV DNA test&#xD;
                  (https://www.cdc.gov/hepatitis/HBV/PDFs/SerologicChartv8.pdf)&#xD;
&#xD;
               2. Hepatitis C virus (HCV) based on HCV-antibody assay (unless associated with a&#xD;
                  negative HCV RNA test)&#xD;
&#xD;
               3. Human immunodeficiency virus (HIV) based on test results that are associated with&#xD;
                  an acquired immunodeficiency syndrome (AIDS)-defining condition or a CD4 count&#xD;
                  ≤200 cells/mm3&#xD;
&#xD;
          -  Known hypersensitivity reaction to efgartigimod, rHuPH20, or 1 of its excipients&#xD;
&#xD;
          -  Previously participated in a clinical trial with efgartigimod and have received at&#xD;
             least 1 administration of the IMP&#xD;
&#xD;
          -  Pregnant or lactating females and those who intend to become pregnant during the trial&#xD;
             or within 90 days after last dose of the IMP&#xD;
&#xD;
          -  Clinically significant uncontrolled active or chronic bacterial, viral, or fungal&#xD;
             infection at screening&#xD;
&#xD;
          -  Any other known autoimmune disease that, in the opinion of the investigator, would&#xD;
             interfere with an accurate assessment of clinical symptoms of ITP or put the&#xD;
             participant at undue risk&#xD;
&#xD;
          -  Clinical evidence of significant unstable or uncontrolled acute or chronic diseases&#xD;
             other than ITP (eg, cardiovascular, pulmonary, hematologic, gastrointestinal,&#xD;
             endocrine, hepatic, renal, neurological, malignancy, infectious diseases, uncontrolled&#xD;
             diabetes) despite appropriate treatments which could put the participant at undue risk&#xD;
&#xD;
          -  Current or history of (ie, within 12 months of screening) alcohol, drug, or medication&#xD;
             abuse&#xD;
&#xD;
          -  Received a live/live-attenuated vaccine less than 4 weeks before screening. The&#xD;
             receipt of any inactivated, sub-unit, polysaccharide, or conjugate vaccine at any time&#xD;
             before screening is not considered an exclusion criterion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Antonio Guglietta, MD</last_name>
    <phone>857-350-4834</phone>
    <phone_ext>+1</phone_ext>
    <email>clinicaltrials@argenx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator Site 0010116</name>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0010079</name>
      <address>
        <city>Lisle</city>
        <state>Illinois</state>
        <zip>60187</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0010062</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0010083</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0540001</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0540003</name>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0610009</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0610004</name>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0610002</name>
      <address>
        <city>Box Hill</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0610010</name>
      <address>
        <city>Clayton</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0610012</name>
      <address>
        <city>Garran</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0610011</name>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0610003</name>
      <address>
        <city>West Perth</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0610005</name>
      <address>
        <city>Westmead</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3590015</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0560002</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0560003</name>
      <address>
        <city>Viña Del Mar</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9950006</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9950007</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>ClinicalTrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9950008</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9950009</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9950011</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0300008</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0300007</name>
      <address>
        <city>Patra</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3530002</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9720013</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9720010</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9720008</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9720011</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 9720007</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390037</name>
      <address>
        <city>Alessandria</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390032</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0390044</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810056</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810053</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810051</name>
      <address>
        <city>Kitakyushu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810054</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810018</name>
      <address>
        <city>Maebashi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810057</name>
      <address>
        <city>Morioka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810017</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810016</name>
      <address>
        <city>Shibukawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810039</name>
      <address>
        <city>Shinagawa-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810038</name>
      <address>
        <city>Tama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810052</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810048</name>
      <address>
        <city>Tsukuba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810044</name>
      <address>
        <city>Yamanashi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0810012</name>
      <address>
        <city>Ōgaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0820005</name>
      <address>
        <city>Seongnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0820003</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0820004</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0820006</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0820007</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0820008</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0520002</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0520004</name>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0520003</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0640001</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0640005</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0640002</name>
      <address>
        <city>Palmerston North</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0470002</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0470003</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480026</name>
      <address>
        <city>Nowy Sącz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0480033</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3510006</name>
      <address>
        <city>Braga</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3510005</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3510007</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 3510001</name>
      <address>
        <city>Porto</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0400005</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0400006</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0400009</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0400012</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0400007</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0400011</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0400008</name>
      <address>
        <city>Târgu-Mureş</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070026</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070038</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070037</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070024</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070025</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0070039</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340024</name>
      <address>
        <city>Alava</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340023</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340037</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340022</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0340036</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0660001</name>
      <address>
        <city>Bangkok Noi</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0660002</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0660003</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0660004</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0660009</name>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0660006</name>
      <address>
        <city>Pathum Thani</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900007</name>
      <address>
        <city>Adapazarı</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900003</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900006</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900008</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900015</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900016</name>
      <address>
        <city>Edirne</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900013</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900004</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900014</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900018</name>
      <address>
        <city>Malatya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900010</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900009</name>
      <address>
        <city>Samsun</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900017</name>
      <address>
        <city>Tekirdağ</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Investigator Site 0900019</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Guglietta, MD</last_name>
      <phone>857-350-4834</phone>
      <phone_ext>+1</phone_ext>
      <email>clinicaltrials@argenx.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Georgia</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 18, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

